Method Article
Presented here is a protocol to measure absolute myocardial flow and resistance using continuous thermodilution in patients with ischemia and nonobstructive coronary artery disease.
In approximately half of the patients undergoing coronary angiography for angina pectoris or for signs or symptoms suggestive of ischemic heart disease, no obstructive coronary artery disease is angiographically visible. The majority of these patients with angina or ischemia and no obstructive coronary artery disease (INOCA) have an underlying coronary vasomotor dysfunction, and current consensus documents recommend diagnostic invasive coronary vasomotor function testing (CFT).
During CFT, a variety of vasomotor dysfunction endotypes can be assessed, including vasospastic coronary dysfunction (epicardial or microvascular vasospasm), and/or microvascular vasodilatory dysfunction, including impaired vasodilatory capacity and increased microvascular resistance. The quantification of the continuous thermodilution derived absolute coronary blood flow and resistance might be a better measure compared to the currently used standard physiologic measures. This article provides an overview of this continuous thermodilution method.
In approximately half of the patients undergoing coronary angiography for angina pectoris or for signs or symptoms suggestive of ischemic heart disease, no obstructive coronary artery disease is angiographically visible1. The majority of these patients with angina or ischemia and no obstructive coronary artery disease (INOCA) have an underlying coronary vasomotor dysfunction, and current ESC guidelines and a recent ESC position paper on INOCA recommend diagnostic invasive coronary vasomotor function testing (CFT)1,2.
During CFT, a variety of vasomotor dysfunction endotypes can be assessed, including vasospastic coronary dysfunction (epicardial or microvascular vasospasm), and/or microvascular vasodilatory dysfunction, including impaired vasodilatory capacity and increased microvascular resistance. Consensus criteria for these endotypes have been defined by the Coronary Vasomotion Disorders International Study Group (COVADIS)3,4.
While vasospastic coronary dysfunction is generally demonstrated by acetylcholine provocation testing, the diagnosis of microvascular vasodilatory dysfunction is more complex. This diagnosis is made by an abnormal index of microvascular resistance (IMR) and/or coronary flow reserve (CFR)4.
Two methods exist for the measurement of IMR or CFR: thermodilution or Doppler flow velocity. Both use intravenous adenosine to induce maximal hyperemia (and thus minimal resistance), and both methods have been extensively validated. However, they do have several important shortcomings: the need for adenosine limits their use in patients with severe chronic obstructive pulmonary disease or asthma. Also, the thermodilution method may overestimate the CFR and has a large intra-observer variability, and with the Doppler flow velocity methods it can be challenging to obtain a stable Doppler flow signal5. Most importantly, both CFR and IMR are only surrogate measures and fail to quantify true coronary blood flow and resistance.
Absolute coronary blood flow (Q) and resistance (R) can be directly quantified with the use of a recently validated and novel method that uses continuous thermodilution with intracoronary saline infusion at room-temperature to induce hyperemia. A dedicated monorail infusion catheter and a pressure wire with temperature sensors enables direct quantification of Q and R, without the use of adenosine. This novel method has been shown to be safe, highly reproducible and operator-independent 6,7.
As has been urged by a recent consensus statement, we need a better understanding of the underlying mechanism of myocardial ischemia in patients with INOCA, across the different endotypes1. This could have major implications for treatment and prognosis. The quantification of the absolute coronary blood flow and resistance might be a better measure compared to the currently used standard physiologic measures. It was recently shown that continuous thermodilution measurements are associated with symptoms in INOCA, while IMR and CFR were not8. Additional outcome data will follow. In this article, the continuous thermodilution protocol is described.
The following protocol was approved by the local medical ethics committee at the Radboudumc hospital, Nijmegen, the Netherlands. The following steps should be followed when performing continuous thermodilution to calculate absolute flow and resistance.
1. Preparations
2. Diagnostic Coronary Angiography
3. Set up of continuous thermodilution measurements
4. Continuous thermodilution measurements
5. Calculation of absolute flow and absolute resistance
NOTE: As shown in Figure 1, the dedicated monorail infusion catheter allows the infusion of saline only through four outer side holes, resulting in complete and optimal mixing with blood; two inner side holes allow the measurement of temperature by the used guidewire.
Figure 2 shows a representative measurement performed in patient A with no obstructive CAD on coronary angiography. The LAD artery was measured using continuous thermodilution to calculate absolute Q and R. The red and green lines represent pressure measurements, and the blue line represents the temperature curve. The infusion rate was set at 20 mL/min (Qi) since the LAD artery was measured. At point 1, the infusion was started and the temperature measured at the distally placed pressure wire declined. After reaching a steady state distal temperature (T =-0.48 °C compared to blood temperature), the pressure wire was pulled back into the infusion catheter (point 2) to measure the proximal temperature at a steady state (Ti = -5.69 °C compared to blood temperature). After this, the infusion is stopped and temperature returns to the zeroed value (point 3). Subsequently, the absolute Q and R are automatically calculated using the formula further specified in section 5. Absolute Q was calculated at 239 mL/min, R at 294 WU with an FFR of 0.89. These flow and resistance rates are considered normal12. Note that the FFR value reflects the actual value (i.e., with the monorail infusion catheter in the distal coronary artery during hyperemia induced by room-temperature saline). The monorail infusion catheter creates a small gradient and hereby actual FFR values might be slightly higher.
Figure 3 represents a similar patient B with no visual signs of obstructive CAD in which the LAD artery was measured as well. Using the continuous thermodilution method in a similar manner, absolute Q is calculated at 157 mL/min, R at 606 WU, and an FFR of 0.89. Note that the absolute Q is lower and R is higher in patient B compared to the measurements in patient A represented in Figure 2.
Figure 1: Example of a dedicated monorail infusion catheter. This image shows an example of a dedicated monorail infusion catheter with 4 outer side holes and 2 inner side holes. Please click here to view a larger version of this figure.
Figure 2: Example continuous thermodilution measurement in patient A with normal flow and resistance. The upper half of the image represents the pressure measurements, the lower half the temperature measurements. Notice the temperature is set to zero to correspond to the temperature of blood. When continuous infusion with room-temperature saline is initiated (1), the temperature in the distal LAD lowers to -0.48 °C. When the pressure wire is pulled back into the infusion catheter (2), the temperature decreases to -5.69 °C. With an infusion rate of 20 mL/min, the calculated Q is 239 mL/min and, taking into account a Pd of 70 mm Hg, R is 294 WU. FFR = fractional flow reserve, Pd = distal coronary pressure, Pa = aortic pressure, T = distal, Ti = infusion temperature, Q = absolute flow, R = resistance, WU = Woods Units. Please click here to view a larger version of this figure.
Figure 3: Example continuous thermodilution measurement in patient B with low flow and high resistance. Similar measurement setup as in Figure 2. Again, the LAD artery is measured and the temperature is set to zero to correspond to the temperature of blood. When continuous infusion with room-temperature saline is initiated (1), the temperature in the distal LAD in this patient lowers to -0.68 °C. When the pressure wire is pulled back into the infusion catheter (2), the temperature decreases to -4.97 °C. With an infusion rate of 20 mL/min, the calculated Q is 157 mL/min and, taking into account a Pd of 96 mm Hg, R is 606 WU. This is a low Q and high R in a patient with no obstructive CAD. Abbreviations are similar to those used in Figure 1. Please click here to view a larger version of this figure.
Continuous thermodilution is an accurate method to measure absolute coronary flow and resistance, which has been shown to strongly agree with the gold standard [15O2]H2O PET derived flow and resistance5. These measurements are of special interest in INOCA patients, with current clinical guidelines recommending the assessment of coronary flow and resistance in this group.
Fractional flow reserve (FFR), the ratio of the maximal myocardial blood flow to the theoretical normal maximal flow, is a well-known hyperemic physiological index for evaluation of functional significance of stenoses in the epicardial coronary artery. Pressure can be used as a surrogate of flow, assuming that resistance is minimal and constant during maximal hyperemia. Therefore, FFR is calculated by dividing the coronary pressure distal of the stenosis, by the aortic pressure during maximal hyperemia. In clinical practice, maximal hyperemia is evoked by administration of intracoronary of intravenous adenosine. But during the assessment of the microcirculation, flow and pressure are also assessed during maximum hyperemia. One of the advantages of the continuous thermodilution method is that adenosine is not needed to induce maximum hyperemia. The intracoronary infusion of room temperature saline induces steady-state maximal hyperemia, and previous studies have shown a high agreement between adenosine- and saline- induced hyperemic FFR 5,7. Therefore, with simultaneous assessment of saline-induced hyperemic FFR (flow), Q and R, epicardial obstructive coronary artery disease can be excluded and the microvascular function assessed. That being said, FFR (flow) reflects the actual FFR value with the pressure wire in the distal coronary artery. If the FFR (flow) is normal, standard FFR measurement will be normal (and even higher in most cases) as well. But in case of grey zone FFR (flow) values, normal FFR could be assessed separately.
Another advantage of the method is the true quantitative assessment of actual blood flow and microvascular resistance. This makes the method especially suitable for intra-patient comparison such as before and after medical treatment or percutaneous coronary intervention.
Troubleshooting of the technique
There are some practical issues to keep in mind. First, make sure to use the right materials and instruments for the measurements. The dedicated monorail infusion catheter is compatible with a 6 French guiding catheter or larger. Also, the infusion pump used for the infusion of saline should be pressure-limited to avoid coronary complications. The heating element of the infusion system should be switched off to ensure that the saline is at room-temperature (and thus induces hyperemia when administered intracoronary). There should be enough saline (approximately 50 mL) in the infusion system: approximately 50 mL of saline is needed to complete one measurement.
Second, make sure to perform the measurements in a uniform manner. Wait long enough until stable hyperemia occurs, indicated by stable Pa, Pd and T values, before pulling back the pressure wire into the monorail catheter. Third, in case of an AV-block, the infusion should be stopped and AV-conduction should recover immediately.
The significance with respect to existing methods
We have recently described the use of continuous thermodilution in INOCA8. In 84 patients with INOCA, we assessed the relationship between Q and R with established CFR and IMR measurements, and the prediction of angina. The median absolute Q was 198 mL/min, and the median absolute R was 416 WU. Absolute R was higher in patients with microvascular vasodilatory dysfunction. Furthermore, Q and R were associated with self-reported angina. CFR and IMR were not associated with angina. This hypothesis-generating study needs confirmation in a larger cohort.
Safety and reproducibility
The safety and reproducibility of continuous thermodilution has been shown previously7,13. In the first study, in 135 patients who were referred for coronary angiography and underwent continuous thermodilution, no significant adverse events were observed7. In 8.1% of the patients, bradycardia and concomitant atrioventricular block appeared transiently during saline infusion. In 2.2% of patients, chest discomfort was experienced during saline infusion in the LAD without accompanying ischemic electrocardiographic changes. In all cases, symptoms disappeared after stopping the saline infusion. In the second study, continuous thermodilution was performed in 100 patients. In one patient, a catheter-induced dissection was observed requiring PCI 13. In 2.6% of all measurements, bradycardia or atrioventricular block occurred. Finally, two patients experienced chest discomfort during infusion without electrocardiographic abnormalities. In the first cohort of patients, reproducibility was assessed by performing duplicate measurements in 80 patients. Duplicate measurements had a strong correlation both for Q (ρ=0.841, P<0.001; intraclass correlation coefficient=0.89, P<0.001) and R (ρ=0.780, P<0.001; intraclass correlation coefficient=0.89, P<0.001).7
Future applications and studies performed in other clinical settings
Continuous thermodilution has been used in different clinical settings. In patients with ST-elevation myocardial infarction (STEMI), the guideline-recommended treatment is primary percutaneous coronary intervention (PCI) to ensure early mechanical reperfusion of the epicardial coronary artery. In over 95% of PCI procedures, the epicardial coronary blood flow is restored. However, in about half of the patients, perfusion to the coronary microvasculature is not fully restored. This is associated with increased morbidity and mortality14. Therefore, besides INOCA, STEMI is an important clinical setting to measure microvascular vasodilatory function. In a prospective study of 32 STEMI patients, continuous thermodilution was used to measure R, and bolus thermodilution was used to measure IMR and CFR immediately after primary percutaneous coronary intervention in the culprit coronary artery6. R was associated with IMR-defined microvascular vasodilatory dysfunction, and a R threshold of greater than 552 WU was optimal for predicting microvascular vasodilatory dysfunction defined by IMR > 40. A second study in 20 STEMI patients demonstrated a decrease in R in the first days after myocardial infarction, reflecting recovery of microvascular vasodilatory dysfunction over time15.
In an exploratory study, the effects on Q and R have been assessed in patients undergoing PCI of a chronic total occlusion of an epicardial artery14. Continuous thermodilution measurements were performed in 25 patients immediately after successful PCI and at short-term follow-up in this pilot. Absolute coronary blood flow in the recanalized artery increased during follow-up in the days after the PCI. In addition, absolute resistance decreased. This study shows the potential to assess treatment effects using continuous thermodilution.
Limitations of the method: normal values in INOCA
In contrast to IMR and CFR, the continuous thermodilution variables Q and R have not yet been prospectively validated. Therefore, no 'normal' range of values for continuous thermodilution parameters are currently available. However, data on clinical outcomes after coronary vasoreactivity testing including continuous thermodilution are necessary for further validation.
Important in the interpretation of continuous thermodilution measurements is the interindividual variability owing to the myocardial mass underlying the coronary artery of interest12. For example, a relatively high flow could be normal in a patient if the dependent perfusion territory is small, but low for another patient with a large perfusion territory. Therefore, estimation of myocardial mass by non-invasive imaging might be necessary to interpret absolute flow and resistance to compare values between patients. More data is necessary on the importance of myocardial mass and potential corrections to the used formulas.
Invasive absolute flow and resistance measurements are safe and reproducible. Future studies are warranted to determine the prognostic value as well as the value to guide therapy in INOCA patients.
Peter Damman received lecture and/or consultancy fees from Phillips and Abbott Vascular.
None.
Name | Company | Catalog Number | Comments |
Rayflow multipurpose infusion catheter | Hexacath | RFW61S | Only compatible with 6F guiding catheter |
PressureWire X guidewire | Abbott | C12059 | Wireless guidewire with distal temperature and pressure sensor |
Coroventis CoroFlow Cardiovascular System software | Coroventis | N/A | Advanced platform to measure physiological indices |
Illumena Neo injector or similar injector system | Liebel-Flarsheim | GU01181006-E | Any injector with pressure limit (600 psi) and adjustable flow and volume injection rate |
100 ml NaCl 0.9% at room temperature |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved